Vaccine Development Against Trypanosoma cruzi and Chagas Disease

Juan C. Vázquez-Chagoyán, Shivali Gupta, Nisha Garg

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.

Original languageEnglish (US)
Pages (from-to)121-146
Number of pages26
JournalAdvances in Parasitology
Volume75
DOIs
StatePublished - 2011

Fingerprint

Chagas Disease
Trypanosoma cruzi
Vaccines
Pathology
Antigens
Thromboembolism
Ventricular Fibrillation
Disease Progression
Immunity
Animal Models
Heart Failure
Infection
Research

Keywords

  • Adjuvants
  • Chagas
  • Immunity
  • Therapeutic and prophylactic vaccine
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Parasitology

Cite this

Vaccine Development Against Trypanosoma cruzi and Chagas Disease. / Vázquez-Chagoyán, Juan C.; Gupta, Shivali; Garg, Nisha.

In: Advances in Parasitology, Vol. 75, 2011, p. 121-146.

Research output: Contribution to journalArticle

Vázquez-Chagoyán, Juan C. ; Gupta, Shivali ; Garg, Nisha. / Vaccine Development Against Trypanosoma cruzi and Chagas Disease. In: Advances in Parasitology. 2011 ; Vol. 75. pp. 121-146.
@article{521fcaaa3e7448b9a75a865898d0d148,
title = "Vaccine Development Against Trypanosoma cruzi and Chagas Disease",
abstract = "The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.",
keywords = "Adjuvants, Chagas, Immunity, Therapeutic and prophylactic vaccine, Trypanosoma cruzi",
author = "V{\'a}zquez-Chagoy{\'a}n, {Juan C.} and Shivali Gupta and Nisha Garg",
year = "2011",
doi = "10.1016/B978-0-12-385863-4.00006-X",
language = "English (US)",
volume = "75",
pages = "121--146",
journal = "Advances in Parasitology",
issn = "0065-308X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Vaccine Development Against Trypanosoma cruzi and Chagas Disease

AU - Vázquez-Chagoyán, Juan C.

AU - Gupta, Shivali

AU - Garg, Nisha

PY - 2011

Y1 - 2011

N2 - The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.

AB - The pathology of Chagas disease presents a complicated and diverse picture in humans. The major complications and destructive evolutionary outcomes of chronic infection by Trypanosoma cruzi in humans include ventricular fibrillation, thromboembolism and congestive heart failure. Studies in animal models and human patients have revealed the pathogenic mechanisms during disease progression, pathology of disease and features of protective immunity. Accordingly, several antigens, antigen-delivery vehicles and adjuvants have been tested to elicit immune protection to T. cruzi in experimental animals. This review summarizes the research efforts in vaccine development against Chagas disease during the past decade.

KW - Adjuvants

KW - Chagas

KW - Immunity

KW - Therapeutic and prophylactic vaccine

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=79961011048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961011048&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-385863-4.00006-X

DO - 10.1016/B978-0-12-385863-4.00006-X

M3 - Article

VL - 75

SP - 121

EP - 146

JO - Advances in Parasitology

JF - Advances in Parasitology

SN - 0065-308X

ER -